Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Chemometrics, Pharmacometrics and Econometrics Dimensions_of_Quality


Published on

25 May 2012 Basel, Switzerland. A philosophical exploration - Scientific understanding and risk-based regulatory decisions on Quality by Design. How good are the scientific explanations in regulatory submissions? Scientific explanations yield understanding; quality of explanations differ.What role can Chemometrics, Pharmacometics and Econometrics play? Understanding multidisciplinary (cGMP, CMC, Clin. Pharm., Tox., Clinical, Public Health) perspectives on risk is important. Opportunities; only when the disciplinary divides are bridged. Within the regulatory realm how we set specifications and assess risk have progressed incrementally; at this rate the Vision 2020 may be expected to be visible broadly over time, by 2020?

  • Be the first to comment

Chemometrics, Pharmacometrics and Econometrics Dimensions_of_Quality

  1. 1. Ajaz S. Hussain, Ph.D.Fellow, Swiss Society for PharmaceuticalSciencesNew Affiliation:Chief Scientific Officer & PresidentBiotechnologyWockhardt Ltd.Chemometrics, Pharmacometrics andEconometrics Dimensions of Quality byDesign5/25/20121
  2. 2. A philosophical explorationScientific understanding and risk-basedregulatory decisions on Quality by Design5/25/20122
  3. 3. Motivation FDA Initiatives launched a decade ago have had a profoundimpact on the global pharmaceutical sector Process Analytical Technology Quality by Design Efforts to conducts risk-based regulatory review and inspections Good guidelines and significant regulatory efforts around the world Significant industrial programs and efforts Academic programs and scholarly contributions Yet, the number of „compliance issues‟, „recalls‟, „drugshortages‟, „warning letters‟, etc., today rival thesituation a decade ago Why? What is missing? How can we improve thesituation?5/25/20123
  4. 4. Looking back, brieflyHow good are the scientific explanations inregulatory submissions?5/25/20124
  5. 5. Dr. Woodcock‟s Challenge in 2000“Will this $ X00 million consent decree improve quality of the real[physical] product?How effective is “process validation”? Is it not just a “well-rehearseddemonstration…. 3 times”?Is our system truly a “modern quality system”?Are our “specifications” based on sound science and riskprinciples?How is “c” in cGMP established?Do current regulations support “continuous improvement”?How efficient is pharmaceutical manufacturing?5/25/20125
  6. 6. Compliance and noncomplianceare complex behaviorsThe product of habits and routines.AutomaticThe intentional pursuit of various goals,such as to maximize one‟s utility, fulfill amoral obligation such as duty or trust, ordispose of one‟s fear of sanctions.PlannedCan be the result of regulatees‟incapacity, incompetence, ignorance ormisunderstanding of regulatoryprescriptions.OtherBrehm and Hamilton (1996)5/25/20126
  7. 7. Framing & conceptualizing“I can see clearly now”Vision 2020“Scientific explanationyields understanding” Perspectives onRegulation: Law,Discretion, andBureaucratic Behavior(Kagan and Scholz, May1980) „Good citizens‟ Vs.{„political citizens,„incompetent‟, and/or„amoral‟} For FDA to be science andrisk-based it needsscientific data &
  8. 8. Making the case (in the US) for CMCreview of development reportsCreating a common ICH vision (“desired state”)to develop ICH Q8, Q9 and Q105/25/20128
  9. 9. How good are the scientificexplanations in regulatorysubmissions?First principlesMechanisticunderstandingCausal links –predictperformanceUnivariatemethodsEmpirical data viatrial-n-error• Variability in cGMPcompliance?,• Variability in critical toquality attributes (e.g.,within and between lots;also now individualunits),• Variability in PK/PD &outcome (e.g., intra- andinter- individualvariability),• Other …….Humans aredriven toacquire andprovideexplanations(but notnecessarily toregulators).5/25/20129
  10. 10. Three perspectives on improving scientificunderstanding through development reports(2003)Developmentreports still astumblingblock in GMPInitiativeDevelopment reports remain a point ofcontention …. manufacturers are skepticalabout how FDA will use the data,…. howmuch information to share with the agencyAjaz Hussain(FDA, CDER) "What is needed is the knowledge that iscaptured within that report, ….." He saidthat if companies can share thatknowledge, the agency can …. set moremeaningful specifications to manage thosechanges in less burdensome ways”.
  11. 11. Three perspectives on improving scientificunderstanding through development reports(2003)DougEllsworth(FDA NewJerseyDistrictOffice)Currently the agency spends a lot of time looking atdeviations, failure investigations, things that are aresult of a less- than- ideal product or processknowledge. "Well know were getting close wheninvestigators can spend more time on adequacy ofthe quality system and not necessarily how theproduct has been adequately validated," he said.GerryMigliaccio(Global QAChief,Pfizer)"We will have a victory if I can sit back and set Pfizerquality standards based on regulations and guidancedocuments not based on warning letters and 483s…will improve our process, ..requirements arepredictable and the process for getting that changeis streamlined, straightforward and very timely. .. achange that can be done without prior approval,where weve demonstrated the knowledge of ourprocess."5/25/201211
  12. 12. FDA & ICH InitiativesPAT Initiative• Guidance +Review,Compliance &Inspection TeamICHGuidelines• Q8, Q9 andQ10 (Q11)Additionally• Office ofGeneric Drug’sefforts5/25/201212
  13. 13. Scientific explanations yieldunderstanding; quality of explanationsdifferMaking a Case for Regulatory Utility ofChemometrics, Pharmacometrics andEconometrics5/25/201213
  14. 14. Although understanding arises fromexplanation, a question remainsExplanation could besubjective -- a feeling ofgrasping the connectionbetween explanandum andexplanans; if so• Such understanding would bedenied any epistemological statusTherefore, scientificunderstanding, in a regulatorycontext, best communicated …• Explanation,• Prediction, and• ConfirmationTHE EPISTEMOLOGICAL STATUS OF SCIENTIFIC THEORIES: AN INVESTIGATION OF THESTRUCTURAL REALIST ACCOUNT Ioannis Votsis, LONDON SCHOOL OF ECONOMICS ANDPOLITICAL SCIENCE (2004) 5/25/201214how do you know what you know?
  15. 15. What is scientific and what is not?The U.S. Supreme Court: An Evolved Theory of Science(2000)The theoretical underpinnings of the methodsmust yield testable predictions by means ofwhich the theory could be falsifiedThere should be a known rate of error thatcan be used in evaluating the results.The methods should preferably be publishedin a peer-reviewed journal.The methods should be generally acceptedwithin the relevant scientific communityFrancis Bacon‟sScientific MethodKarl Popper‟sFalsification TheoryThomas Kuhn‟sParadigm Shifts$file/sciman00.pdf 5/25/201215
  16. 16. Analysis of KnowledgeTruth—andFalsity…—before beliefsThe Correct Analysis ofKnowledgeS is [internally/externally]justified in believing thatp.S believes <that> p.S is justified inbelieving <that> p.p is true.S knows p.Unconscious Knowledge and Epistemic Status. LUÍS M. AUGUSTO. UNIVERSITY OF SUSSEX, June5/25/201216
  17. 17. Prescription for troubleHow flaw in FDA safety net may poserisk to public with generic drugs• Tom Abate, Todd Wallack, Chronicle Staff Writers• San Francisco Chronicle. Sunday, December 22,2002The issues• “[Company X] had tested its generic with chocolatemilk. [Ref.product] was chased with apple juice.”• “Did that matter?”
  18. 18. What role can Chemometrics, Pharmacometicsand Econometrics play?The Correct Analysis ofKnowledgeS believes <that> p.S is justified inbelieving <that> p.p is true.S knows p.Unconscious Knowledge and Epistemic Status. LUÍS M. AUGUSTO. UNIVERSITY OF SUSSEX, June5/25/201218Build a case example viadiscussion with the audience
  19. 19. Epistemological Status of RiskUnderstanding multidisciplinary (cGMP, CMC,Clin. Pharm., Tox., Clinical, Public Health)perspectives on risk is important5/25/201219
  20. 20. Is risk a metaphysical or anepistemological category?the mental state of an individual who experiencesuncertainty or doubt or worry as to the outcome ofa given event.Subjectiverisk:the variation that occurs when actual losses differfrom expected losses.Objectiverisk:the combination of probability and negativeconsequence that exists in the real world.Real risk:the measurement of that combination obtained byconstructing a model of the real world.Observedrisk:the rough estimate of real risk made by anuntrained member of the general public.Perceivedrisk:A disciplinary perspective on the epistemological status of risk. Catherine Althaus. Risk Analysis (2005)5/25/201220
  21. 21. Distinguishing risk fromuncertaintyRisk can be considered as an orderedapplication of knowledge to the unknownDifferent disciplines have a particularknowledge approach with which they confrontthe unknown so as to order its randomnessand convert it into a risk propositionA disciplinary perspective on the epistemological status of risk. Catherine Althaus. Risk Analysis (2005)5/25/201221
  22. 22. This concept of risk can act as amirrorReflecting thepreoccupations,strengths, andweaknesses ofeach disciplineas they grapplewith uncertainty• Acceptable variance in cGMP compliance,critical to quality attributes (in the context ofsafety and efficacy)?5/25/201222A disciplinary perspective on the epistemological status of risk. Catherine Althaus. Risk Analysis (2005)
  23. 23. Preoccupations, strengths, andweaknesses of each disciplineRegulatory utility of pharmacometrics has advanced rapidly inFDA and EMA; it is having a significant impact on clinical trialdesigns and science and risk-based decisions in the clinicalpharmacology disciplinesRegulatory utility of chemometrics is sporadic and withdifficulties; there are lessons to be learned from regulatoryapplications of pharmacometricscGMP risk classifications remain subjective to a large degree;utility, within regulatory agencies, of econometric approaches isworth considering5/25/201223
  24. 24. Opportunities; only when thedisciplinary divides are bridged• Estimate of variance in PK/PD &outcomes (e.g., intra- and inter-individual variability)Pharmacometrics• Estimate of variance in critical to qualityattributes (in the context of PK/PDvariability)Chemometrics• Estimate of variance in cGMPcompliance (in the context of acceptablevariance in critical to quality attributes)Econometrics?5/25/201224
  25. 25. Why? What is missing? How canwe improve the situation?The FDA & ICH initiatives haveprovided incentives for a fewcompanies to progress aheadsignificantly, with new technologiesand systems, while others have notWithin the regulatory realm how weset specifications and assess riskhave progressed incrementally; atthis rate the Vision 2020 may beexpected to be visible broadly overtime, by 2020?5/25/201225
  26. 26. Backup slides5/25/201226
  27. 27. Econometric analysis?Does offshore productionpose an added quality riskrelative to domesticproduction?“Our findings indicate thatPuerto Rico plants operatewith a significantly higherquality risk than matchingplants operated by thesame firm located in themainland U.S., onaverage.”• If so, what factorsinfluence the quality risk?• Quality risk in offshoremanufacturing: Evidencefrom the pharmaceuticalindustry. Volume 29,Issues 7–8, November2011, Pages 737–752,Journal of OperationsManagement5/25/201227
  28. 28. Chemometrics The chemical discipline that uses mathematicaland statistical methods, (a) to design or selectoptimal measurement procedures andexperiments, and (b) to provide maximumchemical information by analyzing chemical data.5/25/201228
  29. 29. Other examplesScale-up factor 10X“3 batches” in process validation“Significant body of data” for stability requirments80 – 125%How do you know what you know?5/25/201229
  30. 30. Process understanding (PATGuidance)A process is generally considered well understoodwhen• (1) all critical sources of variability are identified and explained;• (2) variability is managed by the process; and,• (3) product quality attributes can be accurately and reliablypredicted over the design space established for materials used,process parameters, manufacturing, environmental, and otherconditions.The ability to predict reflects a high degree ofprocess understanding.• Although retrospective process capability data are indicative ofa state of control, these alone may be insufficient to gauge orcommunicate process understanding. 5/25/201230